These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37105495)

  • 1. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
    Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
    Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
    Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
    Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring
    Mansoor A; Akhter A; Hamidi M; Roshan TM; Shabani-Rad MT; Stewart D
    Anticancer Res; 2023 Nov; 43(11):4801-4807. PubMed ID: 37909960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
    Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
    Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.
    Shi D; Gao L; Wan XC; Li J; Tian T; Hu J; Zhang QL; Su YF; Zeng YP; Hu ZJ; Yu BH; Li XQ; Wei P; Li JW; Zhou XY
    BMC Med; 2022 Dec; 20(1):483. PubMed ID: 36522654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
    Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/β-catenin Pathway.
    Jin W; Wang X
    Ann Clin Lab Sci; 2022 May; 52(3):359-366. PubMed ID: 35777795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.
    Liang Y; Wang H; Luo B
    Clin Transl Oncol; 2023 Oct; 25(10):2884-2891. PubMed ID: 36991219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Shi X; Cui Z; Liu X; Wu S; Wu Y; Fang F; Zhao H
    Biochem Biophys Res Commun; 2019 Mar; 510(4):594-600. PubMed ID: 30739786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothesis of Opposite Interplay Between the Canonical WNT/beta-catenin Pathway and PPAR Gamma in Primary Central Nervous System Lymphomas.
    Vallée A; Lecarpentier Y; Vallée JN
    Curr Issues Mol Biol; 2019; 31():1-20. PubMed ID: 30647194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
    Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
    Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphomas with plasmablastic differentiation.
    Teruya-Feldstein J
    Curr Oncol Rep; 2005 Sep; 7(5):357-63. PubMed ID: 16091196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Meng H; Zhao B; Wang Y
    Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient.
    Pokhrel A; Yuldasheva O; Mirashi E; Nair K; Salyana M; Jaswani V; Avezbakiyev B; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096211065633. PubMed ID: 35073776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.
    Wang Z; Ran X; Qian S; Hou H; Dong M; Wu S; Ding M; Zhang Y; Zhang X; Zhang M; Chen Q
    Arch Biochem Biophys; 2021 Oct; 710():108998. PubMed ID: 34280359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma.
    Hashimoto N; Ueda T; Hiraiwa S; Tajiri T; Nakamura N; Yokoyama K
    Case Rep Hematol; 2020; 2020():8876567. PubMed ID: 33335784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat.
    Dholaria B; Alapat D; Pandey T; Agarwal A
    Med Oncol; 2012 Dec; 29(5):3529-34. PubMed ID: 22562157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.